John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$257M |
| 2 |
Boston Scientific
BSX
|
+$228M |
| 3 |
Meta Platforms (Facebook)
META
|
+$225M |
| 4 |
Amazon
AMZN
|
+$220M |
| 5 |
S&P Global
SPGI
|
+$219M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$252M |
| 2 |
PayPal
PYPL
|
+$252M |
| 3 |
Walt Disney
DIS
|
+$217M |
| 4 |
Chevron
CVX
|
+$206M |
| 5 |
Best Buy
BBY
|
+$152M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.83% |
| 2 | Consumer Discretionary | 13.53% |
| 3 | Financials | 9.1% |
| 4 | Healthcare | 9.07% |
| 5 | Consumer Staples | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
Element Solutions
ESI
$8.59B
| $315K | ﹤0.01% |
17,784
-2,358
| -12% | -$32.6K |
|
2827
First Community Bankshares
FCBC
$933M
| $315K | ﹤0.01% |
14,579
-13,676
| -48% | -$287K |
|
2828
PUT
TE Connectivity
TEL
$58B
| $315K | ﹤0.01% |
+2,600
| New | +$287K |
|
|
NAGE
2829
Niagen Bioscience
NAGE
$254M
| $315K | ﹤0.01% |
65,611
-12,095
| -16% | -$59K |
|
|
ZEN
2830
PUT
DELISTED
ZENDESK INC
ZEN
| $315K | ﹤0.01% |
2,200
+200
| +10% | +$24.8K |
|
|
SREV
2831
DELISTED
ServiceSource International, Inc.
SREV
| $315K | ﹤0.01% |
179,199
-43,763
| -20% | -$64.7K |
|
2832
CALL
Edison International
EIX
$28.8B
| $314K | ﹤0.01% |
+5,000
| New | +$301K |
|
2833
Houlihan Lokey
HLI
$9B
| $314K | ﹤0.01% |
4,676
-1,354
| -22% | -$87.8K |
|
|
NGHC
2834
DELISTED
National General Holdings Corp
NGHC
| $313K | ﹤0.01% |
+9,148
| New | +$311K |
|
2835
PUT
H&R Block
HRB
$6.54B
| $312K | ﹤0.01% |
+19,700
| New | +$340K |
|
2836
PUT
Robert Half
RHI
$4.58B
| $312K | ﹤0.01% |
+5,000
| New | +$298K |
|
|
KRA
2837
DELISTED
Kraton Corporation
KRA
| $312K | ﹤0.01% |
+11,225
| New | +$303K |
|
2838
Accel Entertainment
ACEL
$962M
| $311K | ﹤0.01% |
+30,837
| New | +$323K |
|
2839
PUT
Cheesecake Factory
CAKE
$5.65B
| $311K | ﹤0.01% |
8,400
-9,700
| -54% | -$333K |
|
|
K
2840
PUT
DELISTED
Kellanova
K
| $311K | ﹤0.01% |
5,325
-3,621
| -40% | -$218K |
|
2841
CALL
New York Times
NYT
$11B
| $311K | ﹤0.01% |
+6,000
| New | +$267K |
|
2842
CALL
Synopsys
SNPS
$78.1B
| $311K | ﹤0.01% |
+1,200
| New | +$277K |
|
|
DRNA
2843
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $310K | ﹤0.01% |
14,091
-122,908
| -90% | -$2.71M |
|
2844
Ashland
ASH
$3.39B
| $309K | ﹤0.01% |
+3,902
| New | +$295K |
|
2845
Kinetik
KNTK
$4.4B
| $308K | ﹤0.01% |
+12,960
| New | +$190K |
|
2846
SelectQuote
SLQT
$91.3M
| $308K | ﹤0.01% |
14,856
-63,144
| -81% | -$1.3M |
|
2847
Hanmi Financial
HAFC
$920M
| $307K | ﹤0.01% |
+27,073
| New | +$271K |
|
2848
PUT
Lumen
LUMN
$5.96B
| $307K | ﹤0.01% |
+31,500
| New | +$311K |
|
2849
US Gold Corp
USAU
$268M
| $307K | ﹤0.01% |
+18,522
| New | +$187K |
|
|
LL
2850
CALL
DELISTED
LL Flooring Holdings, Inc.
LL
| $307K | ﹤0.01% |
+10,000
| New | +$278K |
|
Similar funds
John Overdeck's Q4 2020 Portfolio in Review
As of Q4 2020, John Overdeck held 3,971 positions worth $34.9B, up 24% from $28.2B the previous quarter. Its ten largest holdings account for 7.4% of the portfolio.
John Overdeck deployed $1.95B of net new capital in Q4 2020, opening 955 new positions and adding to 1,167 existing holdings. Its largest new stake was Boston Scientific: 6,312,819 shares worth $227M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Chevron, an estimated $206M trimmed.
- John Overdeck's largest Q4 2020 buy was Boston Scientific: 6,312,819 shares worth $227M.
- John Overdeck added most to NVIDIA in Q4 2020, an estimated $257M increase.
- John Overdeck's biggest Q4 2020 reduction was Chevron, cutting an estimated $206M.
- John Overdeck fully exited Pfizer in Q4 2020, selling an estimated $252M.
- John Overdeck's ten largest holdings make up 7.4% of its $34.9B portfolio in Q4 2020.
- John Overdeck opened 955 new positions and closed 694 in Q4 2020.
- John Overdeck's portfolio value rose 24% quarter-over-quarter to $34.9B.
Based on Two Sigma Investments's 13F filing for Q4 2020, filed 16 Feb 2021.